Research Progress on Sunitinib-associated Cardiotoxicity

Sunitinib is a small-molecule, multi-targeted tyrosine kinase inhibitor widely used in the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumor and gastrointestinal stromal tumors. Sunitinib demonstrates significant clinical efficacy, yet it is associated with severe cardiotoxicity. Specific manifestations include QT interval prolongation, decreased left ventricular ejection fraction, heart failure, and even sudden cardiac death. Currently, the precise mechanisms underlying sunitinib-related cardiotoxicity remain unclear, and there is a lack of evidence-based preventive and therapeutic measures. This article reviewed the latest research on sunitinib-related cardiotoxicity, providing a reference for addressing practical clinical issues.